NEW YORK/PHILADELPHIA (Reuters) - Onyx Pharmaceuticals Inc said on Monday it has agreed to buy Proteolix Inc, a privately held biotechnology company developing cancer drugs, for an upfront cash payment of $276 million, sending its shares up more than 7 percent.